Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pyrotinib + trastuzumab + docetaxel
- Development stage
- Phase 3
- Lead developer
- Jiangsu HengRui Medicine Co., Ltd.
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Pyrotinib + trastuzumab + docetaxel is a combination regimen used primarily for the treatment of HER2-positive metastatic breast cancer. Pyrotinib is an oral, irreversible pan-ErbB receptor tyrosine kinase inhibitor that targets EGFR, HER2, and HER4. Trastuzumab is a monoclonal antibody targeting the extracellular domain of the HER2 receptor. Docetaxel is a taxane-class chemotherapeutic agent that inhibits microtubule depolymerization. The combination has demonstrated significant improvement in progression-free survival compared to placebo plus trastuzumab and docetaxel in patients with untreated HER2-positive metastatic breast cancer, as shown in phase 3 clinical trials such as PHILA[1][3][4]. This regimen leverages synergistic mechanisms to overcome dependence on the HER2 signaling cascade.
- Brand names
- Herceptin (trastuzumab)Taxotere (docetaxel)
02
Targets
EGFR (Epidermal growth factor receptor)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB4 (Erb-b2 receptor tyrosine kinase 4)VEGFR2 (Vascular endothelial growth factor receptor 2)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on pyrotinib + trastuzumab + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pyrotinib + trastuzumab + docetaxel.